{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T15:08:37Z","timestamp":1749049717992,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Complex medication schedules in Parkinson\u2019s disease (PD) result in lower therapy adherence, which contributes to suboptimal therapy and clinical deterioration. Medication reminder systems might improve therapy adherence and subsequently improve symptoms of PD. This randomized controlled study assessed the effect of the electronic medication dispenser Medido on physical disability in PD, as a proxy for changes in therapy adherence.x<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Eighty-seven patients were randomized into the Medido group or control group. The primary outcome of physical disability was measured by the AMC Linear Disability Scale (ALDS). Secondary outcomes were quality of life (QoL) (PDQ-39), health status (EQ5D-5L, VAS), non-motor symptoms (NMS-Quest), and QoL of the caregiver (PDQ-carer). Measurements were performed at baseline, and after 3 and 6\u2009months follow-up.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>When using the Medido, a non-significant improvement of 3.0 points (95% CI -5.6;11.6) was seen in ALDS. The exploratory subgroup Hoehn &amp; Yahr classification (H&amp;Y) &gt;\u20092.5 improved significantly on ALDS with 14.7 points (95% CI -28.5;-0.9, <jats:italic>p<\/jats:italic>\u2009=\u20090.029 for group x time interaction). QoL deteriorated with 1.0 point in PDQ-39 (<jats:italic>p<\/jats:italic>\u2009=\u20090.01 for group x time interaction) in favor of the control group. Non-significant differences were observed for VAS (0.4 points, <jats:italic>p<\/jats:italic>\u2009=\u20090.057) and NMS-Quest (1.3 points, <jats:italic>p<\/jats:italic>\u2009=\u20090.095) in favor of the Medido group. No changes over time were observed in EQ5D-5L and PDQ-carer.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Based on these data, no firm conclusion can be drawn, but use of the Medido medication dispenser may result in a clinical improvement of physical disability and seems particularly appropriate for more severe patients.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.trialregister.nl\/trial\/3753\">NTR3917<\/jats:ext-link>. Registered 19 March 2013.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12877-019-1292-y","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T15:10:13Z","timestamp":1571238613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A randomized controlled efficacy study of the Medido medication dispenser in Parkinson\u2019s disease"],"prefix":"10.1186","volume":"19","author":[{"given":"K.","family":"Hannink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"ter Brake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.G.M.","family":"Oonk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.","family":"Wertenbroek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Piek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Vree-Egberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Faber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"van der Palen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8540-7624","authenticated-orcid":false,"given":"L.D.","family":"Dorresteijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"issue":"3","key":"1292_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1136\/practneurol-2012-000463","volume":"13","author":"PF Worth","year":"2013","unstructured":"Worth PF. When the going gets tough: how to select patients with Parkinson\u2019s disease for advanced therapies. Pract Neurol. 2013;13(3):140\u201352. \n                    https:\/\/doi.org\/10.1136\/practneurol-2012-000463\n                    \n                  .","journal-title":"Pract Neurol"},{"issue":"3","key":"1292_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/mds.21831","volume":"23","author":"AS Kulkarni","year":"2008","unstructured":"Kulkarni AS, Balkrishnan R, Anderson RT, Edin HM, Kirsch J, Stacy MA. Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson\u2019s disease. Mov Disord. 2008;23(3):359\u201365. \n                    https:\/\/doi.org\/10.1002\/mds.21831\n                    \n                  .","journal-title":"Mov Disord"},{"key":"1292_CR3","doi-asserted-by":"publisher","unstructured":"Wei Y-J, Palumbo FB, Simoni-Wastila L, Shulman LM, Stuart B, Beardsley R, et al. Antiparkinson drug use and adherence in medicare part D beneficiaries with Parkinson\u2019s disease. Clin Ther. 2013;35(10):1513\u20131525.e1. \n                    https:\/\/doi.org\/10.1016\/j.clinthera.2013.09.001\n                    \n                  .","DOI":"10.1016\/j.clinthera.2013.09.001"},{"issue":"4","key":"1292_CR4","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/mds.22999","volume":"25","author":"KL Davis","year":"2010","unstructured":"Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson\u2019s disease: evidence from administrative claims data. Mov Disord. 2010;25(4):474\u201380. \n                    https:\/\/doi.org\/10.1002\/mds.22999\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"11","key":"1292_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/mds.20602","volume":"20","author":"KA Grosset","year":"2005","unstructured":"Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson\u2019s disease. Mov Disord. 2005;20(11):1502\u20137. \n                    https:\/\/doi.org\/10.1002\/mds.20602\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"11","key":"1292_CR6","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/mds.20525","volume":"20","author":"KA Grosset","year":"2005","unstructured":"Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson\u2019s disease. Mov Disord. 2005;20(11):1397\u2013404. \n                    https:\/\/doi.org\/10.1002\/mds.20525\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"2","key":"1292_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/0002512-200926020-00006","volume":"26","author":"JL Bainbridge","year":"2009","unstructured":"Bainbridge JL, Ruscin JM. Challenges of treatment adherence in older patients with Parkinson\u2019s disease. Drugs Aging. 2009;26(2):145\u201355.","journal-title":"Drugs Aging"},{"issue":"15","key":"1292_CR8","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/mds.22589","volume":"24","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson\u2019s disease. Mov Disord. 2009;24(15):2175\u201386. \n                    https:\/\/doi.org\/10.1002\/mds.22589\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"15","key":"1292_CR9","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1002\/mds.23394","volume":"25","author":"DA Gallagher","year":"2010","unstructured":"Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson\u2019s disease and are we missing them? Mov Disord. 2010;25(15):2493\u2013500. \n                    https:\/\/doi.org\/10.1002\/mds.23394\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"7","key":"1292_CR10","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/j.1468-1331.2010.03320.x","volume":"18","author":"F Valldeoriola","year":"2011","unstructured":"Valldeoriola F, Coronell C, Pont C, Buongiorno MT, C\u00e1mara A, Gaig C, et al. Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson\u2019s disease: the ADHESON study. Eur J Neurol. 2011;18(7):980\u20137. \n                    https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03320.x\n                    \n                  .","journal-title":"Eur J Neurol"},{"key":"1292_CR11","doi-asserted-by":"publisher","unstructured":"Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X, Keepanasseril A, et al. Interventions for enhancing medication adherence. Nieuwlaat R, ed. Cochrane Database Syst Rev. 2008;(2):CD000011. \n                    https:\/\/doi.org\/10.1002\/14651858.CD000011.pub3","DOI":"10.1002\/14651858.CD000011.pub3"},{"issue":"3","key":"1292_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1517\/17425247.2011.556616","volume":"8","author":"S Md","year":"2011","unstructured":"Md S, Haque S, Sahni JK, Baboota S, Ali J. New non-oral drug delivery systems for Parkinson\u2019s disease treatment. Expert Opin Drug Deliv. 2011;8(3):359\u201374. \n                    https:\/\/doi.org\/10.1517\/17425247.2011.556616\n                    \n                  .","journal-title":"Expert Opin Drug Deliv"},{"key":"1292_CR13","unstructured":"Press WH, Teukolsky SA, Vetterling WT, Flannery BP. Numerical recipes in C: the art of scientific computing. Cambridge: Cambridge University Press; 1992."},{"key":"1292_CR14","unstructured":"Medido Connected. Innospense. \n                    http:\/\/www.medido.com\n                    \n                  . Accessed May 27, 2019."},{"issue":"8987","key":"1292_CR15","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(95)92404-3","volume":"346","author":"AM Lozano","year":"1995","unstructured":"Lozano AM, Lang AE, Galvez-Jimenez N, et al. Effect of GPi pallidotomy on motor function in Parkinson\u2019s disease. Lancet. 1995;346(8987):1383\u20137.","journal-title":"Lancet"},{"issue":"23","key":"1292_CR16","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1212\/01.wnl.0000295666.30948.9d","volume":"69","author":"N Weisscher","year":"2007","unstructured":"Weisscher N, Post B, de Haan RJ, Glas CAW, Speelman JD, Vermeulen M. The AMC linear disability score in patients with newly diagnosed Parkinson disease. Neurology. 2007;69(23):2155\u201361. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000295666.30948.9d\n                    \n                  .","journal-title":"Neurology"},{"issue":"Suppl 1","key":"1292_CR17","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1007\/PL00007730","volume":"245","author":"V Peto","year":"1998","unstructured":"Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson\u2019s disease quality of life questionnaire and its associated measures. J Neurol. 1998;245(Suppl 1):S10\u20134.","journal-title":"J Neurol"},{"issue":"1","key":"1292_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/jnnp.69.1.67","volume":"69","author":"A Schrag","year":"2000","unstructured":"Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2000;69(1):67\u201373.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"1292_CR19","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/mds.20844","volume":"21","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: the NMSQuest study. Mov Disord. 2006;21(7):916\u201323. \n                    https:\/\/doi.org\/10.1002\/mds.20844\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"5","key":"1292_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.parkreldis.2012.01.007","volume":"18","author":"C Jenkinson","year":"2012","unstructured":"Jenkinson C, Dummett S, Kelly L, Peters M, Dawson J, Morley D, et al. The development and validation of a quality of life measure for the carers of people with Parkinson\u2019s disease (the PDQ-Carer). Parkinsonism Relat Disord. 2012;18(5):483\u20137. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2012.01.007\n                    \n                  .","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"1292_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","volume":"4","author":"GM Sullivan","year":"2012","unstructured":"Sullivan GM, Feinn R. Using effect size-or why the P value is not enough. J Grad Med Educ. 2012;4(3):279\u201382. \n                    https:\/\/doi.org\/10.4300\/JGME-D-12-00156.1\n                    \n                  .","journal-title":"J Grad Med Educ"},{"issue":"e1","key":"1292_CR22","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1093\/jamia\/ocu047","volume":"22","author":"N Mistry","year":"2015","unstructured":"Mistry N, Keepanasseril A, Wilczynski NL, et al. Technology-mediated interventions for enhancing medication adherence. J Am Med Inform Assoc. 2015;22(e1):e177\u201393. \n                    https:\/\/doi.org\/10.1093\/jamia\/ocu047\n                    \n                  .","journal-title":"J Am Med Inform Assoc"},{"issue":"11","key":"1292_CR23","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1089\/tmj.2013.0014","volume":"19","author":"T Ker\u00e4nen","year":"2013","unstructured":"Ker\u00e4nen T, Liikkanen S. Medication reminder service for mobile phones: an open feasibility study in patients with Parkinson\u2019s disease. Telemed J E Health. 2013;19(11):888\u201390. \n                    https:\/\/doi.org\/10.1089\/tmj.2013.0014\n                    \n                  .","journal-title":"Telemed J E Health"},{"issue":"9","key":"1292_CR24","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/mds.21453","volume":"22","author":"JN Caviness","year":"2007","unstructured":"Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, et al. Defining mild cognitive impairment in Parkinson\u2019s disease. Mov Disord. 2007;22(9):1272\u20137. \n                    https:\/\/doi.org\/10.1002\/mds.21453\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"3 Suppl","key":"1292_CR25","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ncl.2013.04.013","volume":"31","author":"VW Sung","year":"2013","unstructured":"Sung VW, Nicholas AP. Nonmotor symptoms in Parkinson\u2019s disease: expanding the view of Parkinson\u2019s disease beyond a pure motor, pure dopaminergic problem. Neurol Clin. 2013;31(3 Suppl):S1\u201316. \n                    https:\/\/doi.org\/10.1016\/j.ncl.2013.04.013\n                    \n                  .","journal-title":"Neurol Clin"},{"issue":"12","key":"1292_CR26","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s00415-012-6557-8","volume":"259","author":"A Antonini","year":"2012","unstructured":"Antonini A, Barone P, Marconi R, Morgante L, Zappulla S, Pontieri FE, et al. The progression of non-motor symptoms in Parkinson\u2019s disease and their contribution to motor disability and quality of life. J Neurol. 2012;259(12):2621\u201331. \n                    https:\/\/doi.org\/10.1007\/s00415-012-6557-8\n                    \n                  .","journal-title":"J Neurol"},{"issue":"4","key":"1292_CR27","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jval.2014.03.002","volume":"17","author":"P Cub\u00ed-Moll\u00e1","year":"2014","unstructured":"Cub\u00ed-Moll\u00e1 P, de Vries J, Devlin N. A study of the relationship between health and subjective well-being in Parkinson\u2019s disease patients. Value Heal. 2014;17(4):372\u20139. \n                    https:\/\/doi.org\/10.1016\/j.jval.2014.03.002\n                    \n                  .","journal-title":"Value Heal"},{"issue":"5","key":"1292_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487\u201397. \n                    https:\/\/doi.org\/10.1056\/NEJMra050100\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1292_CR29","doi-asserted-by":"publisher","first-page":"h4672","DOI":"10.1136\/bmj.h4672","volume":"351","author":"P Sedgwick","year":"2015","unstructured":"Sedgwick P, Greenwood N. Understanding the Hawthorne effect. BMJ. 2015;351:h4672. \n                    https:\/\/doi.org\/10.1136\/bmj.h4672\n                    \n                  .","journal-title":"BMJ"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-019-1292-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12877-019-1292-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-019-1292-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T23:18:59Z","timestamp":1602717539000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-019-1292-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1292"],"URL":"https:\/\/doi.org\/10.1186\/s12877-019-1292-y","relation":{},"ISSN":["1471-2318"],"issn-type":[{"type":"electronic","value":"1471-2318"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"14 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the granted by the Medical Ethics Committee Twente, the Netherlands (reference number NL43868.044.13). Written informed consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"273"}}